Company Description

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.

The company’s lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.

It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Nkarta, Inc.

Country	United States
Founded	2015
IPO Date	Jul 10, 2020
Industry	Biotechnology
Sector	Healthcare
Employees	157
CEO	Paul Hastings

Contact Details

Address: 1150 Veterans Boulevard South San Francisco, California 94080 United States
Phone	925 407 1049
Website	nkartatx.com

Stock Details

Ticker Symbol	NKTX
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$18.00
CIK Code	1787400
CUSIP Number	65487U108
ISIN Number	US65487U1088
Employer ID	47-4515206
SIC Code	2834

Key Executives

Name	Position
Paul J. Hastings	Chief Executive Officer and Director
Dr. Nadir Mahmood Ph.D.	President and Principal Accounting and Financial Officer
Dr. Shawn Rose M.D., Ph.D.	Chief Medical Officer and Head of Research and Development

Latest SEC Filings

Date	Type	Title
Nov 24, 2025	SCHEDULE 13D/A	Filing
Nov 14, 2025	SCHEDULE 13G/A	Filing
Nov 10, 2025	10-Q	Quarterly Report
Nov 10, 2025	8-K	Current Report
Oct 17, 2025	SCHEDULE 13G/A	Filing
Aug 12, 2025	10-Q	Quarterly Report
Aug 12, 2025	8-K	Current Report
Jun 6, 2025	8-K	Current Report
May 14, 2025	10-Q	Quarterly Report
May 14, 2025	8-K	Current Report

View All SEC Filings